GO
Loading...

Medicine

More

  • Qiagen Q3 profit rises on demand for disease diagnostics Wednesday, 29 Oct 2014 | 4:01 PM ET

    Oct 29- German genetic testing specialist Qiagen NV reported a 6 percent increase in adjusted third-quarter earnings, slightly ahead of analysts' average forecast, helped by demand for its automated diagnostics gear and for test kits co-developed with drugmakers. Qiagen this week unveiled an agreement with Japan's Astellas Pharma to develop diagnostics...

  • FDA approves vaccine to block meningitis strain Wednesday, 29 Oct 2014 | 3:32 PM ET

    The Food and Drug Administration said Wednesday it cleared Pfizer's Trumenba to prevent a subtype of Meningococcal disease in people ages 10 to 25. When the bacteria infect the bloodstream they cause sepsis. Last year the University of California, Santa Barbara and Princeton University both experienced separate, unrelated outbreaks of meningococcal...

  • UPDATE 1-Pfizer meningitis vaccine wins U.S. approval Wednesday, 29 Oct 2014 | 3:06 PM ET

    Oct 29- Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday. It is the first approved U.S. vaccine that prevents invasive disease caused by the bacterium Neisseria meningitidis B, a...

  • AP IMPACT: US health care unprepared for Ebola Wednesday, 29 Oct 2014 | 12:37 PM ET

    The U.S. health care apparatus is so unprepared and short on resources to deal with the deadly Ebola virus that even small clusters of cases could overwhelm parts of the system, according to an Associated Press review of readiness at hospitals and other components of the emergency medical network. Experts broadly agree that a widespread nationwide outbreak...

  • Funding to tame an Ebola outbreak has fallen short Wednesday, 29 Oct 2014 | 12:29 PM ET

    Randall Larsen, the former executive director of the Congressional Commission on the Prevention of Weapons of Mass Destruction. Health and Human Services preparedness office. "It was recognized that there would be a dual benefit from research on vaccines, therapeutics and diagnostics to counter bioterror threats and emerging infectious diseases," said...

  • AP IMPACT: If Ebola batters US, we are not ready Wednesday, 29 Oct 2014 | 12:00 PM ET

    The U.S. health care apparatus is so unprepared and short on resources to deal with the deadly Ebola virus that even small clusters of cases could overwhelm parts of the system, according to an Associated Press review of readiness at hospitals and other components of the emergency medical network. Experts broadly agree that a widespread outbreak across the...

  • Lilly, Boehringer revise terms of diabetes drugs alliance Wednesday, 29 Oct 2014 | 8:55 AM ET

    Oct 29- Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries. Under the alliance signed in 2011, the companies had agreed to develop and market diabetes drugs together. Boehringer and Eli Lilly said on Wednesday that they would continue joint development and marketing of...

  • Feds: Engineer's sleepiness caused derailment Wednesday, 29 Oct 2014 | 6:59 AM ET

    William Rockefeller's sleepiness was due to a combination of an undiagnosed disorder— sleep apnea— and a drastic shift in his work schedule, the National Transportation Safety Board said. The board also issued rulings on four other Metro-North accidents that occurred in New York and Connecticut in 2013 and 2014, repeatedly finding fault with the railroad...

  • Captured Australian weight-loss conman convicted Wednesday, 29 Oct 2014 | 1:10 AM ET

    CANBERRA, Australia— An Australian man who promoted fake slimming products was convicted Wednesday of assaulting police and resisting arrest during his recent capture after a year on the run. Police found Foster hiding in scrub Tuesday near the resort town of Byron Bay, 800 kilometers north of Sydney. Foster also created political controversy in Britain when...

  • Rising health-care costs not a trend: Aetna CEO Tuesday, 28 Oct 2014 | 4:56 PM ET
    Mark Bertolini, CEO of Aetna.

    People may be worried that health-care costs will increase and become a trend, Aetna's CEO said he's not.

  • Receptos moves on IBD drug potential     Tuesday, 28 Oct 2014 | 1:08 PM ET

    Receptos CEO Faheem Hasnain discusses the company's pipeline and outcomes for inflammatory bowel disease and multiple sclerosis patients.

  • Swiss agency approves trial for Ebola vaccine Tuesday, 28 Oct 2014 | 6:24 AM ET

    GENEVA— The Swiss agency that regulates new drugs said Tuesday it has approved an application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital. In a statement, the Bern- based Swiss government agency said the trial continues a series that began in the United States, Britain and Mali, using a vaccine based on a...

  • Ebola vaccine candidate     Monday, 27 Oct 2014 | 2:02 PM ET

    Discussing the development of an Ebola vaccine, with Stanley Erck, Novavax CEO.

  • Oct 24- Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. Other approved hemophilia B treatments include Baxter's Rixubis, Pfizer Inc's Benefix and CSL Behring Ltd's Mononine. Baxter's shares were up about 1 percent at $69.66 in early...

  • Sarepta tumbles on new delay for key drug Monday, 27 Oct 2014 | 10:54 AM ET

    Sarepta says the FDA wants to have further discussions and could impose more requirements later on. It is Sarepta's most advanced experimental drug and the company has asked the FDA for expedited approval. In early 2013 the Cambridge, Massachusetts, company said the FDA asked for more information about the drug.

  • Boy hospitalized in NYC for possible Ebola symptoms Monday, 27 Oct 2014 | 9:36 AM ET

    The 5-year-old arrived in New York from Guinea and had a 103 degree fever, according to media reports.

  • Oct 27- Akebia Therapeutics Inc said its lead experimental drug was successful in raising and maintaining hemoglobin levels in certain patients with anemia related to chronic kidney disease. About 30 million people in the United States have chronic kidney disease, with an estimated 1.8 million of these patients suffering from anemia, the company said on...

  • New test can spot Ebola in 30 minutes: Report Monday, 27 Oct 2014 | 8:23 AM ET

    Researchers say they have developed a test that can diagnose Ebola within 30 minutes, the BBC reports.

  • Oct 27- Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had asked for additional data on its lead drug, delaying its marketing application by about six months. The FDA gave Sarepta a fresh lease of life in April when the agency indicated an alternate approval pathway for the drug, eteplirsen, after deeming Sarepta's plans for marketing...

  • Merck 3Q adjusted profit tops analysts' estimates Monday, 27 Oct 2014 | 7:09 AM ET

    Merck also announced on Monday that the Food and Drug Administration gave breakthrough therapy designation to Keytruda for advanced non-small cell lung cancer that has progressed on or following platinum-based chemotherapy. Analysts surveyed by Zacks Investment Research expected earnings of 88 cents per share. Revenue declined to $10.56 billion from...